Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: KHS who wrote (20598)	4/15/1999 11:30:00 PM
From: Mkilloran	Read Replies (1) \| Respond to of 23519

KHS...domestic sales have been flat , milestone payments are known $4 million...the only way they get to $0.12 cents is with international sales ....things are looking up for a good run and higher prices into the 2nd qtr...with better sales in the future...current and future earnings will drive VVUS much higher Let the fun begin

To: KHS who wrote (20598)	4/16/1999 12:13:00 AM
From: VLAD	Read Replies (2) \| Respond to of 23519

KHS, My guess on Q1 product sales goes something like this: 1)Domestic sales about $3.5M 2)International sales about 1/2 of Q4 1998--my guess is about $3.5M 3)Milestone payments of $4M accounts for 12.5 cents profits. In other words the CFO has done an EXCELLENT job controlling expenses because without the milestones, Vivus managed to break even. No marketing arm in the US market and a delayed European launch means a lot of room for some serious earnings improvements looking forward. With AstraZeneca's European launch of MUSE next month along with a probable domestic partner in the near future, Vivus can see some SERIOUS earnings looking forward. IMHO based on forward looking earnings potential Vivus is CHEAP even at $10.00/share.